Morepen Laboratories Ltd

Net profit of Morepen Laboratories rose 17.27% to Rs 40.87 crore in the quarter ended September 2025 as against Rs 34.85 crore during the previous quarter ended September 2024. Sales declined 5.97% to Rs 411.58 crore in the quarter ended September 2025 as against Rs 437.73 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales411.58437.73 -6 OPM %7.4610.07 - PBDT31.1547.88 -35 PBT19.8646.02 -57 NP40.8734.85 17 Powered by Capital Market - Live

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live

The key equity benchmarks continued to trade with decent gains in morning trade. Market sustained upward momentum amid recent GST tax cuts. Upcoming inflation numbers due later this week will guide the market's next direction. The Nifty traded above the 24,800 level. IT shares advanced after declining in the past five trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex gained 203.42 points or 0.25% to 80,990.72. The Nifty 50 index rose 51.25 points or 0.21% to 24,823.30. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.01% and the S&P BSE Small-Cap index jumped 0.08%. The market breadth was strong. On the BSE, 1,968 shares rose and 1,679 shares fell. A total of 208 shares were unchanged. New Listing: Shares of Amanta Healthcare were currently trading at Rs 137 at 10:10 IST on the BSE, representing a premium of 8.73% compared with the issue price of Rs 126. The scrip was listed at Rs 134, exhibiting a premium of 6.35% to the issue price. So far, the stock has hit a high of Rs 140 and a low of Rs 134. On the BSE, over 2.22 lakh shares of the company were traded in the counter so far. The initial public offer (IPO) of Amanta Healthcare was subscribed 82.61 times. The issue opened for bidding on 1 September 2025 and it closed on 3 September 2025. The price band of the IPO was fixed between Rs 120 and 126 per share. Buzzing Index: The Nifty IT index advanced 2% to 34,998.25. The index fell 4% in the past five consecutive trading sessions. Infosys (up 3.84%), Wipro (up 2.38%), Tech Mahindra (up 2.07%), Coforge (up 1.95%), Persistent Systems (up 1.58%), LTIMindtree (up 1.52%), Mphasis (up 1.42%), HCL Technologies (up 1.37%), Oracle Financial Services Software (up 1.15%) and Tata Consultancy Services (up 1.02%) surged. Stocks in Spotlight: Morepen Laboratories rose 3.46% after the company announced that its subsidiary, Morepen Medipath, has signed a joint venture agreement with UAE-based Bimedical FZE. Both partners will contribute equally in the share capital of the new entity, with Morepen Laboratories holding an indirect 30% stake through its subsidiary. ArisInfra Solutions shed 0.93%. The company said that its subsidiary ArisUnitern RE Solutions, together with Vaishnavi Residences, has announced the proposed launch of Arsh Greens'an exclusive community of villa plots within the city limits of Bengaluru. Virtual Galaxy Infotech rallied 4.29% after the company entered into a memorandum of understanding (MoU) with Xangars Infratech Solutions for deployment of 1 lakh UPI and QR-based sound boxes with digital payment solutions in India.Powered by Capital Market - Live

The proposed joint venture company, to be incorporated in India, will focus on manufacturing, trading and selling medical devices. Both partners will contribute equally in the share capital of the new entity, with Morepen Laboratories holding an indirect 30% stake through its subsidiary. The company clarified that the joint venture will be treated as a related party but its promoters have no direct interest apart from their shareholding in Morepen Medipath. Morepen Laboratories is a vertically integrated pharmaceutical and healthcare company delivering APIs, branded generics, medical devices, and consumer wellness products worldwide. On a consolidated basis, net profit of Morepen Laboratories declined 70.28% to Rs 10.75 crore while net sales declined 6.59% to Rs 425.24 crore in Q1 June 2025 over Q1 June 2024. Powered by Capital Market - Live

Morepen Laboratories has received the rating IVR A-/ Stable for long term bank facilities availed by the company. Powered by Capital Market - Live

Morepen Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 6 September 2025.Powered by Capital Market - Live

Net profit of Morepen Laboratories declined 70.28% to Rs 10.75 crore in the quarter ended June 2025 as against Rs 36.17 crore during the previous quarter ended June 2024. Sales declined 6.59% to Rs 425.24 crore in the quarter ended June 2025 as against Rs 455.22 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales425.24455.22 -7 OPM %5.6811.34 - PBDT24.5453.89 -54 PBT15.5248.17 -68 NP10.7536.17 -70 Powered by Capital Market - Live

Net profit of Morepen Laboratories declined 77.00% to Rs 8.06 crore in the quarter ended June 2025 as against Rs 35.05 crore during the previous quarter ended June 2024. Sales rose 1.46% to Rs 391.28 crore in the quarter ended June 2025 as against Rs 385.64 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales391.28385.64 1 OPM %4.8412.61 - PBDT19.2350.64 -62 PBT11.3547.05 -76 NP8.0635.05 -77 Powered by Capital Market - Live

Profit before tax (PBT) fell 67.79% YoY to Rs 15.51 crore in Q1 June 2025. Total expenses rose 0.89% to Rs 414.13 crore in Q1 FY26 compared with Rs 410.47 crore in Q1 FY25. Cost of material consumed stood at Rs 237.70 crore (up 1.14% YoY), employee benefit expenses was at Rs 55.23 crore (up 15.18% YoY), finance cost stood at Rs 4.03 crore (up 250.43% YoY), selling and distribution expenses stood at Rs 30.39 core (up 2.74% YoY) during the period under review. Morepen Laboratories is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering highquality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide.Powered by Capital Market - Live

Morepen Laboratories will hold a meeting of the Board of Directors of the Company on 6 August 2025.Powered by Capital Market - Live